A. Kayabolen

This paper develops ACE2-coated virus-like particles (ACE2-VLPs) that effectively neutralize SARS-CoV-2, including variants, and show superior efficacy compared to ACE2-expressing extracellular vesicles.

The paper introduces EPIKOL, a CRISPR-Cas9 library targeting epigenetic modifiers, and demonstrates its utility in identifying cancer-specific epigenetic vulnerabilities in breast and prostate cancer.

This paper shows Montelukast inhibits SARS-CoV-2 by targeting both Spike/ACE2 and main protease through in silico and in vitro studies.

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.